Loading...
0

Buy Full Version
"China Oncology Drugs Market"

Let us help you !

Invalid Email.

Please Select Country.

Invalid contact no.

Special Symbols Not Allowed.

Invalid Security Code.

Thank You For Your Interest.

We've Successfully Got Your Message,

Our Executive will get back to you Shortly.

China Oncology Drugs Market by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy) and Indication (Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Skin Cancer, Ovarian Cancer, Cervical Cancer, Kidney Cancer, and Other Cancers): Opportunity Analysis and Industry Forecast, 2019-2026

LI_184866
Pages: 135
Aug 2019 | 1126 Views
 
Author(s) : Kavita Joshi & Onkar Sumant , Onkar Sumant
Tables: 35
Charts: 56
 

China Oncology Drugs Market Outlook-2026

The China oncology drugs market was valued at $6,498.2 million in 2018 and is projected to reach $12,688.7 million by 2026, registering a CAGR of 8.7% from 2019 to 2026. Cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. According to the data published by WHO, about 1 in 6 deaths is due to cancer globally. Being the most populous country in the world, cancer rates are significantly rising in China. As per Global Cancer Observatory 2018, the number of new cancer cases registered each year in China are 4,285,033. Amongst which, lung cancer constitutes 18.1%; Colorectum cancer is about 12.2%; Stomach cancer is approximately 10.6%; liver cancer constitutes 9.2%; breast cancer comprises of 8.6%, and other cancers is 41.1%.

China Oncology Drugs Market

Get more information on this report : Request Sample Pages

Rise in incidence of various cancer conditions, aging population, westernized diet, shift to sedentary lifestyle, and surge in tobacco smoke exposure due to urbanization in China are the key factors that drive the growth of the cancer and thus boosting the growth of the China oncology drugs market. Furthermore, rise in cancer awareness and availability of cancer drugs are expected to boost the market growth. However, the use of traditional Chinese medicine (TCM) to cure cancer and high cost involved in new drug development coupled with threat of failure & adverse effects associated with cancer drug therapies are the factors expected to restrain the growth of the market. Conversely, high potential of emerging economies and increase in number of pipeline products are expected to provide new opportunities for market players in future.

China Oncology Drugs Market Segmentation:

The China oncology drugs market is segmented based on drug class type and indication. Depending on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy, and hormonal therapy. By indication, it is categorized into blood cancer, breast cancer, gastrointestinal cancer, prostate cancer, lung cancer, skin cancer, ovarian cancer, cervical cancer, kidney cancer, and other cancers. Region wise, the market is studied across China.

China Oncology Drugs Market by Drug class type

Get more information on this report : Request Sample Pages

Segment Review

Based on drug class type, the China oncology drugs market is divided into chemotherapy, targeted therapy, immunotherapy, and hormonal therapy. According to drug class type, the targeted therapy segment occupied the largest oncology/cancer drugs market share in 2018. This is due to the ability of targeted therapies to kill only malignant cells, higher efficacy, and higher survival rates associated with their use. The immunotherapy segment is expected to show fastest growth during the forecast period registering a CAGR of 10.0%. This is attributed to surge in incidence of cancer in China and high unmet medical needs in some countries. Immunotherapy drugs are widely accepted as an ideal treatment option as these drugs are potentially harmless to the other living cells of the body, which makes them less toxic as compared to other modes of cancer therapies. Moreover, continuous efforts in R&D to design and develop new immunotherapeutic for the treatment of various cancer types serves as a key factor for the growth of the oncology drugs market.

China Oncology Drugs Market by Indication

Get more information on this report : Request Sample Pages

According to indication, the lung cancer segment occupied the largest oncology drugs market share in 2018. This is due to presence of huge geriatric population in China. The breast cancer segment is expected to experience fastest growth during the forecast period. This is due to technological developments in the field of cancer diagnostics and rise in the awareness related to the early diagnosis of cancer.

The China oncology drugs market possesses high growth potential, owing to rise in cancer awareness across the region and increase in R&D investment. Moreover, increase in disposable income; surge in research, development, & innovation activities; and rise in awareness related to different cancers are some other factors, which contribute toward the growth of the oncology/cancer drugs market in this region. In addition, widespread prevalence of certain cancers, such as breast cancer, and presence of huge geriatric population drive the market growth in this region.

The China oncology drugs market is highly competitive and the prominent players in the market have adopted various strategies for increasing their market share. These include expansion of their geographical presence through collaborations, product approval, development, and acquisition. Major players operating in the China oncology drugs market include AbbVie Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Shanghai Junshi Biosciences Co., Ltd., Beigene, and Jiangsu Hengrui Medicine Co., Ltd.

Key Benefits For China Oncology Drugs Market:

  • This report entails a detailed quantitative analysis along with the current China oncology drugs market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
  • The China oncology drugs market forecast is studied from 2019 to 2026.
  • The China oncology drugs market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

Key Market Segments

By Drug Class 

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy Therapy
  • Hormonal Therapy

By Indication

  • Blood Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Prostate Cancer
  • Lung Cancer
  • Skin Cancer
  • Ovarian Cancer
  • Cervical Cancer  
  • Kidney Cancer 
  • Other Cancers 
 

CHAPTER 1:    INTRODUCTION

1.1.    Report description
1.2.    Key benefits for stakeholders
1.3.    Key market segments

1.3.1.    List of key players profiled in the report

1.4.    Research methodology

1.4.1.    Secondary research
1.4.2.    Primary research
1.4.3.    Analyst tools and models

CHAPTER 2:    EXECUTIVE SUMMARY

2.1.    Key findings of the study
2.2.    CXO perspective

CHAPTER 3:    MARKET OVERVIEW

3.1.    Market definition and scope
3.2.    Key findings

3.2.1.    Top investment pockets
3.2.2.    Top winning strategies, 2018

3.3.    Porter’s five forces analysis
3.4.    Market dynamics

3.4.1.    Drivers

3.4.1.1.    Industrial Collaboration
3.4.1.2.    In house manufacturing
3.4.1.3.    Increase in incidences of cancers in the Chinese population

3.4.2.    Restraint

3.4.2.1.    Preference of Generics and Biosimilars

3.4.3.    Opportunity

3.4.3.1.    Increase in number of pipeline drugs

3.4.4.    Impact analyses

CHAPTER 4:    CHINA ONCOLOGY DRUGS MARKET, BY DRUG CLASS TYPE

4.1.    Overview

4.1.1.    Market size and forecast

4.2.    Chemotherapy

4.2.1.    Key market trends, growth factors, and opportunities
4.2.2.    Market size and forecast

4.3.    Targeted therapy

4.3.1.    Key market trends, growth factors, and opportunities
4.3.2.    Market size and forecast

4.4.    Immunotherapy (biologic therapy)

4.4.1.    Key market trends, growth factors, and opportunities
4.4.2.    Market size and forecast

4.5.    Hormonal therapy

4.5.1.    Key market trends, growth factors, and opportunities
4.5.2.    Market size and forecast

CHAPTER 5:    CHINA ONCOLOGY DRUGS MARKET, BY INDICATION

5.1.    Overview

5.1.1.    Cancer Incidences in China, 2018
5.1.2.    Market size and forecast

5.2.    Blood cancer

5.2.1.    Market size and forecast

5.3.    Breast cancer

5.3.1.    Market size and forecast

5.4.    Gastrointestinal and Urinary Cancer

5.4.1.    Market size and forecast
5.4.2.    GB/Cholangiocarcinoma

5.4.2.1.    Market size and forecast

5.4.3.    Bladder Cancer

5.4.3.1.    Market size and forecast

5.4.4.    Pancreatic Cancer

5.4.4.1.    Market size and forecast

5.5.    Prostate cancer

5.5.1.    Market size and forecast

5.6.    Lung cancer

5.6.1.    Market size and forecast
5.6.2.    Small cell lung cancer (SCLC)

5.6.2.1.    Market size and forecast

5.7.    Skin cancer

5.7.1.    Market size and forecast

5.8.    Ovarian cancer

5.8.1.    Market size and forecast

5.9.    Cervical cancer

5.9.1.    Market size and forecast

5.10.    Kidney cancer

5.10.1.    Market size and forecast,

5.11.    Other cancers

5.11.1.    Market size and forecast

CHAPTER 6:    COMPANY PROFILES

6.1.    ABBVIE INC.

6.1.1.    Company overview
6.1.2.    Company snapshot
6.1.3.    Operating business segments
6.1.4.    Product Portfolio
6.1.5.    Business performance

6.2.    ASTELLAS PHARMA INC.

6.2.1.    Company overview
6.2.2.    Company snapshot
6.2.3.    Operating business segments
6.2.4.    Product Portfolio
6.2.5.    Business performance

6.3.    ASTRAZENECA PLC

6.3.1.    Company overview
6.3.2.    Company snapshot
6.3.3.    Operating business segments
6.3.4.    Product Portfolio
6.3.5.    Business performance

6.4.    BRISTOL-MYERS SQUIBB COMPANY

6.4.1.    Company overview
6.4.2.    Company snapshot
6.4.3.    Operating business segments
6.4.4.    Product Portfolio
6.4.5.    Business performance
6.4.6.    Key strategic moves and developments

6.5.    CELGENE CORPORATION

6.5.1.    Company overview
6.5.2.    Company snapshot
6.5.3.    Operating business segments
6.5.4.    Product portfolio
6.5.5.    Business performance
6.5.6.    Key strategic moves and developments

6.6.    F. HOFFMANN-LA ROCHE LTD.

6.6.1.    Company overview
6.6.2.    Company snapshot
6.6.3.    Operating business segments
6.6.4.    Product portfolio
6.6.5.    Business performance
6.6.6.    Key strategic moves and developments

6.7.    JOHNSON & JOHNSON

6.7.1.    Company overview
6.7.2.    Company snapshot
6.7.3.    Operating business segments
6.7.4.    Product portfolio
6.7.5.    Business performance
6.7.6.    Key strategic moves and developments

6.8.    SHANGHAI JUNSHI BIOSCIENCES CO., LTD.

6.8.1.    Company overview
6.8.2.    Company snapshot
6.8.3.    Operating business segments
6.8.4.    Product portfolio
6.8.5.    Business performance
6.8.6.    Key strategic moves and developments

6.9.    BEIGENE

6.9.1.    Company overview
6.9.2.    Company snapshot
6.9.3.    Operating business segments
6.9.4.    Product portfolio
6.9.5.    Business performance
6.9.6.    Key strategic moves and developments

6.10.    JIANGSU HENGRUI MEDICINE CO., LTD.

6.10.1.    Company overview
6.10.2.    Company snapshot
6.10.3.    Operating business segments
6.10.4.    Product portfolio
6.10.5.    Key strategic moves and developments

LIST OF TABLES

TABLE 01.    CHINA ONCOLOGY DRUGS MARKET, BY DRUG CLASS TYPE, 2018-2026 ($MILLION)
TABLE 02.    CHINA ONCOLOGY DRUGS MARKET, LIST OF CHEMOTHERAPY DRUGS
TABLE 03.    CHINA ONCOLOGY DRUGS MARKET, LIST OF TARGETED THERAPY DRUGS
TABLE 04.    CHINA ONCOLOGY DRUGS MARKET, LIST OF IMMUNOTHERAPEUTIC DRUGS
TABLE 05.    CHINA ONCOLOGY DRUGS MARKET, LIST OF HORMONAL THERAPY DRUGS
TABLE 06.    CHINA ONCOLOGY DRUGS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 07.    ABBVIE: COMPANY SNAPSHOT
TABLE 08.    ABBVIE: OPERATING SEGMENTS
TABLE 09.    ABBVIE: PRODUCT PORTFOLIO
TABLE 10.    ASTELLAS: COMPANY SNAPSHOT
TABLE 11.    ASTELLAS: PRODUCTS AND SERVICES
TABLE 12.    ASTELLAS: PRODUCT PORTFOLIO
TABLE 13.    ASTRAZENECA: COMPANY SNAPSHOT
TABLE 14.    ASTRAZENECA: OPERATING SEGMENTS
TABLE 15.    ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 16.    BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 17.    BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 18.    CELGENE: COMPANY SNAPSHOT
TABLE 19.    CELGENE: OPERATING SEGMENTS
TABLE 20.    CELGENE: PRODUCT TYPE PORTFOLIO
TABLE 21.    ROCHE: COMPANY SNAPSHOT
TABLE 22.    ROCHE: OPERATING SEGMENTS
TABLE 23.    ROCHE: PRODUCT TYPE PORTFOLIO
TABLE 24.    J&J: COMPANY SNAPSHOT
TABLE 25.    J&J: OPERATING SEGMENTS
TABLE 26.    J&J: PRODUCT TYPE PORTFOLIO
TABLE 27.    SHANGHAI JUNSHI BIOSCIENCES CO., LTD.: COMPANY SNAPSHOT
TABLE 28.    SHANGHAI JUNSHI BIOSCIENCES CO., LTD: OPERATING SEGMENTS
TABLE 29.    SHANGHAI JUNSHI BIOSCIENCES CO., LTD.: PRODUCT TYPE PORTFOLIO
TABLE 30.    BEIGENE: COMPANY SNAPSHOT
TABLE 31.    BEIGENE: OPERATING SEGMENTS
TABLE 32.    BEIGENE: PRODUCT TYPE PORTFOLIO
TABLE 33.    JIANGSU HENGRUI MEDICINE CO., LTD: COMPANY SNAPSHOT
TABLE 34.    JIANGSU HENGRUI MEDICINE CO., LTD: OPERATING SEGMENTS
TABLE 35.    JIANGSU HENGRUI MEDICINE CO., LTD: PRODUCT TYPE PORTFOLIO

LIST OF FIGURES

FIGURE 01.    CHINA CANCER DRUGS MARKET SEGMENTATION
FIGURE 02.    TOP INVESTMENT POCKETS
FIGURE 03.    TOP WINNING STRATEGIES, 2016–2019*
FIGURE 04.    TOP WINNING STRATEGIES, BY YEAR, 2016–2019*
FIGURE 05.    TOP WINNING STRATEGIES: NATURE AND TYPE, 2016–2019*
FIGURE 06.    MODERATE BARGANING POWER OF BUYERS
FIGURE 07.    HIGH BARGANING POWER OF SUPPLIERS
FIGURE 08.    MODERATE THREAT OF SUBSTITUTION
FIGURE 09.    MODERATE THREAT OF NEW ENTRANTS
FIGURE 10.    HIGH COMPETITIVE RIVALRY
FIGURE 11.    NUMBER OF NEW CASES IN 2018, ALL AGES (%) MALES
FIGURE 12.    NUMBER OF NEW CASES IN 2018, ALL AGES (%) FEMALES
FIGURE 13.    IMPACT ANALYSES
FIGURE 14.    CHEMOTHERAPY MARKET, 2018–2026 ($MILLION)
FIGURE 15.    TARGETED THERAPY MARKET, 2018–2026 ($MILLION)
FIGURE 16.    IMMUNOTHERAPY MARKET, 2018–2026 ($MILLION)
FIGURE 17.    HORMONAL THERAPY MARKET, 2018–2026 ($MILLION)
FIGURE 18.    NUMBER OF CANCER INCIDENCES IN 2018, CHINA
FIGURE 19.    CANCER INCIDENCES IN 2018 & 5 YEAR PREVALANCE, CHINA
FIGURE 20.    CHINA BLOOD CANCER MARKET, 2018–2026 ($MILLION)
FIGURE 21.    CHINA BREAST CANCER MARKET, 2018–2026 ($MILLION)
FIGURE 22.    CHINA GASTROINTESTINAL CANCER MARKET, 2018–2026 ($MILLION)
FIGURE 23.    CHINA GASTROINTESTINAL CANCER MARKET, FOR CHOLANGIOCARCINOMA, 2018–2026 ($MILLION)
FIGURE 24.    CHINA BLADDER CANCER MARKET, FOR BLADDER CANCER, 2018–2026 ($MILLION)
FIGURE 25.    CHINA GASTROINTESTINAL CANCER MARKET, FOR PANCREATIC CANCER, 2018–2026 ($MILLION)
FIGURE 26.    CHINA PROSTATE CANCER MARKET, 2018–2026 ($MILLION)
FIGURE 27.    CHINA LUNG CANCER MARKET, 2018–2026 ($MILLION)
FIGURE 28.    CHINA LUNG CANCER MARKET, 2018–2026 ($MILLION)
FIGURE 29.    CHINA SKIN CANCER MARKET, 2018–2026 ($MILLION)
FIGURE 30.    CHINA OVARIAN CANCER MARKET, 2018–2026 ($MILLION)
FIGURE 31.    CHINA CERVICAL CANCER MARKET, 2018–2026 ($MILLION)
FIGURE 32.    CHINA KIDNEY CANCER MARKET, 2018–2026 ($MILLION)
FIGURE 33.    CHINA OTHER CANCER MARKET, 2018–2026 ($MILLION)
FIGURE 34.    ABBVIE: NET SALES, 2016–2018 ($MILLION)
FIGURE 35.    ABBVIE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 36.    ABBVIE: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 37.    ASTELLAS: SALES, 2016–2018 ($MILLION)
FIGURE 38.    ASTELLAS: SALES SHARE BY PRODUCTS AND SERVICES, 2018 (%)
FIGURE 39.    ASTELLAS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 40.    ASTRAZENECA: REVENUE, 2016–2018 ($MILLION)
FIGURE 41.    ASTRAZENECA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 42.    REVENUE, 2016–2018 ($MILLION)
FIGURE 43.    BRISTOL-MYERS SQUIBB: SALES SHARE BY PRODUCTS AND SERVICES, 2018 (%)
FIGURE 44.    BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 45.    CELGENE: REVENUE, 2016–2018 ($MILLION)
FIGURE 46.    CELGENE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 47.    CELGENE: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 48.    ROCHE: NET SALES, 2016–2018 ($MILLION)
FIGURE 49.    ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 50.    ROCHE: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 51.    J&J: REVENUE, 2016–2018 ($MILLION)
FIGURE 52.    J&J: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 53.    J&J: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 54.    SHANGHAI JUNSHI BIOSCIENCES CO., LTD.: REVENUE, 2016–2018 ($MILLION)
FIGURE 55.    BEIGENE: REVENUE, 2016–2018 ($MILLION)
FIGURE 56.    BEIGENE: REVENUE SHARE BY REGION, 2018 (%)

 
 

The utilization of cancer drugs is expected to witness a significant growth in the near future owing to the rise in incidence of cancer in China. Furthermore, the China oncology drugs market growth is propelled by surge in geriatric population, increase in collaboration between pharmaceutical companies for development of novel cancer drugs, and rise in awareness associated with early detection of cancer among populace. However, complications associated with lower access to cancer medications are expected to hinder the market growth.

Moreover, rise in local players such as Beigene, Jiangsu Hengrui Medicine Co., Ltd. and others and industrial collaborations between the manufacturers is anticipated to propel the market growth in the near future for cancer drugs in China. In addition, initiatives adopted by the Chinese government to lower the price of certain drugs in China further fuels the market growth.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Download Sample

Request Customization

Download Sample

OR

Purchase Full Report of
China Oncology Drugs Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,370
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

FREQUENTLY ASKED
QUESTIONS?

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 
Download Sample